plerixafor 24 mg/1.2mL Injection, Solution, 50 vials — NDC 63552-725-00 (Billing 63552-0725-00)
This is a package of 50 vials of plerixafor 24 mg/1.2mL Injection, Solution from Patheon Manufacturing Services LLC, marketed since Sep 2025 and currently FDA-listed. It is this product's only package size.
NDC database record
One package, one record: these facts belong to NDC 63552-725-00 alone.
- Record
- FDA NDC Directory package listing · Drug for further processing
- Code segments
- 63552 labeler · 725 product · 00 package
- Package marketed since
- Sep 1, 2025
- Listing certified through
- Dec 31, 2026
- Barcode (UPC-A, from the NDC)
- 3 6355272500 6
- FDA record last changed
- Jul 24, 2026
Identity & classification
Regulatory identifiers FDA, NLM and CMS codes for this package
Where does this data come from?
- FDA openFDA NDC Directory · synced Oct 1, 2026
- FDA label on DailyMed · label index refreshed Oct 3, 2026
- RxNorm (NLM RxNav) · catalog refreshed Oct 1, 2026
- Medi-Span GPI (licensed)
- First Databank (licensed) · refreshed Oct 1, 2026
Clinical
Plerixafor 24 mg/1.2mL is an injectable solution containing the active ingredient plerixafor. This medication is typically used to mobilize hematopoietic stem cells (blood-forming cells) in patients preparing for stem cell collection or transplantation. Plerixafor works by affecting how stem cells move within the bone marrow, helping them enter the bloodstream so they can be gathered for medical procedures. This product is classified as a drug for further processing.
Patient education
Supplement & herbal interactions
Where does this data come from?
- MedlinePlus (NLM) · refreshed Oct 1, 2026
- FDA label on DailyMed · label index refreshed Oct 3, 2026
Ask a licensed pharmacist directly — free, answered by our team.
Pricing
A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.
| Price system | Per mL | Per package |
|---|---|---|
| Retail pharmacies payNADAC · weekly | Not in the retail survey — common for institutional, discontinued, or low-volume packs. | |
| Medicaid paysCMS SDUD · 12 mo | No recent Medicaid claims on file for this NDC — rare and low-volume NDCs are suppressed in the public data. | |
| Medicare drug plans payPart D · quarterly | No Part D plan price is available for this NDC in our data. | |
Where does this data come from?
- CMS NADAC weekly file
- CMS ASP pricing files · refreshed Sep 20, 2026
- CMS Medicaid State Drug Utilization Data · refreshed Oct 4, 2026
- CMS Part D plan pricing files · refreshed Sep 24, 2026
- VA National Acquisition Center price file
Packaging — all sizes for this product
| Package NDC | Description | Marketing start | Marketing end | Status |
|---|---|---|---|---|
| 63552-0725-00 You're viewing this Main listing | 50 VIAL, SINGLE-USE in 1 CARTON / 1.2 mL in 1 VIAL, SINGLE-USE | — | — | Active |
Therapeutic equivalents
| Product | Labeler | Pack | NADAC/unit | TE | Status | Price vs. this |
|---|---|---|---|---|---|---|
| Plerixafor 24 mg/1.2mL 70771-1776-01 | Zydus | 1 vial | — | — | FDA listed | — |
| Plerixafor 24 mg/1.2mL 31722-0373-31 | Camber | 1 vial | — | AP | FDA listed | — |
| Plerixafor 24 mg/1.2mL 55150-0356-01 | Eugia | 1 vial | — | AP | FDA listed | — |
| Plerixafor 24 mg/1.2mL 71288-0155-01 | Meitheal | 1 vial | — | AP | FDA listed | — |
| Mozobil 24 mg/1.2mL 00024-5862-01 | Sanofi-Aventis | 1 vial | — | AP | FDA listed | — |
| plerixafor 24 mg/1.2mLthis 63552-0725-00 | Patheon | 50 vials | — | — | FDA listed | — |
| Plerixafor 24 mg/1.2mL 68083-0155-01 | Gland | 1 vial | — | AP | FDA listed | — |
| plerixafor 24 mg/1.2mL 70121-1694-02 | Amneal | 1 vial | — | AP | FDA listed | — |
| Plerixafor 24 mg/1.2mL 72205-0249-01 | Novadoz | 1 vial | — | AP | FDA listed | — |
| Plerixafor 24 mg/1.2mL 70710-1208-01 | Zydus | 1 vial | — | — | FDA listed | — |
| Plerixafor 24 mg/1.2mL 65219-0284-12 | Fresenius | 1 vial | — | AP | FDA listed | — |
| Plerixafor 24 mg/1.2mL 43598-0308-23 | Dr. | 1 vial | — | AP | FDA listed | — |
| Plerixafor 24 mg/1.2mL 72162-2642-02 | Bryant | 1 vial | — | AP | FDA listed | — |
Where does this data come from?
- FDA openFDA NDC Directory · synced Oct 1, 2026
- FDA Orange Book · refreshed Oct 3, 2026
- CMS NADAC weekly file
Availability & generic status
The FDA lists approved generic versions of this medicine, but that does not always mean a pharmacy can get one today. Patent rules, launch agreements, supply and pricing can affect when generics actually arrive.
Where does this data come from?
- FDA Orange Book · refreshed Oct 3, 2026
Inactive Ingredients / Excipients
Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.
Where does this data come from?
IACT rows and label-wide narrative are kept separate; availability and product-level specificity depend on the submitted label.- FDA label on DailyMed · label index refreshed Oct 3, 2026
- FDA openFDA NDC Directory · synced Oct 1, 2026
Inactive ingredient FAQ
Are inactive ingredients the same for every manufacturer?
Why might an inactive ingredient be missing?
Can inactive ingredients matter?
Manufacturer & labeler
More NDCs from Patheon Manufacturing Services LLC labeler code 63552
- lisdexamfetamine dimesylate 20 mg Capsule NDC 63552-288-00
- lisdexamfetamine dimesylate 30 mg Capsule NDC 63552-289-00
- camizestrant 75 mg Tablet, Film Coated NDC 63552-290-00
- FLUZONE HIGH DOSE NORTHERN HEMISPHERE influenza a virus a/victoria/4897/2022 ivr-238 (h1n1) antigen (formaldehyde inactivated), influenza a virus a/croatia/10136/rv/2023 (h3n2) antigen (formaldehyde inactivated), and influenza b virus b/michigan/01/2021 antigen (formaldehyde inactivated) 60 ug/.5mL; 60 ug/.5mL Injection, Suspension NDC 63552-722-10
- nirsevimab 100 mg/mL Injection NDC 63552-723-00
- nirsevimab 100 mg/mL Injection NDC 63552-724-00
Where does this data come from?
- FDA openFDA NDC Directory · synced Oct 1, 2026
- Drugs@FDA
Full FDA label FDA SPL
📄 FDA label ▾
No FDA label is on file for this product yet. Labels load from openFDA / DailyMed and refresh weekly.
Medicare Part D spend CMS · PART D · 2026 (Q1)
About this NDC listing & data coverage
What "drug for further processing" means
FDA lists this package under the "drug for further processing" marketing category: Patheon Manufacturing Services LLC supplies it to other companies for further processing or repackaging (blister cards that are later repackaged or co-packaged are a common example). The units themselves are a finished dosage form — which is why pricing or Medicaid data can still appear — but this exact package code may not be the presentation a retail pharmacy dispenses.
What data is (and isn’t) available for this NDC — tap to expand
| NDC identity (package / product / labeler codes) | ✓ Available |
| Labeler | ✓ Available |
| Product & package description | ✓ Available |
| Marketing category & status | ✓ Available |
| Active ingredient / dosage form / route | ✓ Available |
| FDA label (SPL via DailyMed) | ✓ Available |
| Package photos | — Not published for this NDC No photo available yet for this listing. |
| Inactive ingredients (structured) | — Not published for this NDC The labeler did not submit a structured excipient list, or no SPL is available. |
| NADAC pharmacy acquisition price (CMS) | — Not published for this NDC CMS publishes NADAC only for NDCs reported in its retail-pharmacy survey. |
| Orange Book / therapeutic-equivalence data | — Not published for this NDC Applies only to products approved under an NDA/ANDA; many listings are out of scope. |
| HCPCS J-code billing crosswalk | — Not published for this NDC Most self-administered / retail products have no J-code — that is normal. |
| Medicaid utilization (CMS SDUD) | — Not published for this NDC CMS reports utilization only for NDCs with Medicaid claims above its privacy threshold. |